Physician profile
Michael Englert
NPI 1801988027
$50,123.14
in general payments reported to CMS, 2019-2025
43 companies · $50.17 in 2025
The $50.17 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $13K · 2021: $269 · 2022: $107 · 2023: $64.32 · 2024: $44.86 · 2025: $50.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $19,268.92 | 2019-2020 | |
| Genentech USA, INC. | $13,639.34 | 2019-2020 | |
| Acorda Therapeutics, INC | $12,261.52 | 2019-2021 | |
| Genzyme Corporation | $1,367.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $340.16 | 2019-2020 | |
| Abbvie INC. | $255.68 | 2019-2025 | |
| Livanova USA, INC. | $240.19 | 2019-2020 | |
| Biogen, INC. | $233.39 | 2019-2022 | |
| Allergan, INC. | $196.69 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $190.56 | 2019-2020 | |
| Lundbeck LLC | $161.81 | 2019-2020 | |
| Abbott Laboratories | $147.55 | 2019-2024 | Infinity |
| Jazz Pharmaceuticals INC. | $118.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $116.59 | 2020-2024 | Acthar |
| Teva Pharmaceuticals USA, INC. | $96.96 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Englert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.